Advertisement
"Sprint Force America exemplifies a commitment to active aging," said AlexDrigan, Product Director, EUFLEXXA(TM). "We support this team's dedication tothe sport of track and believe that they can inspire others who want tocontinue doing what they love, regardless of age."
Advertisement
Renowned for their successes in the arena of masters track, Sprint ForceAmerica is based in New York and is comprised of male sprinters aged 40-79.The club competes at many national events, including the Penn Relays, theSummer National Senior Games, and the United States Track and Field mastersnationals, as well as at international championships.
"We are thankful to EUFLEXXA(TM) for this amazing sponsorship," said EdGonera, President and Co-Founder of Sprint Force America. "As a team, we havenever believed that age had to affect our ability to compete and we appreciatethat our new sponsor supports us in our mission to prove that to the rest ofthe world."
About EUFLEXXA(TM)
EUFLEXXA(TM) (1% sodium hyaluronate) is the first and only non-avianderived hyaluronic acid approved in the U.S. for the treatment of pain causedby knee osteoarthritis and continues to be the fastest growing brand of HA onthe market.(1) EUFLEXXA(TM) is indicated for a three-injection treatmentregimen for patients who have failed to respond adequately to conservativenon-pharmacologic therapy and simple analgesics (e.g., acetaminophen). In aprospective, randomized, double-blind, head-to-head study versus the marketleading HA therapy, significantly more patients were "pain-free" and"symptom-free" with EUFLEXXA(TM).(2)
The process used to manufacture EUFLEXXA(TM) produces the HA that mostclosely resembles the HA in healthy human synovial fluid and the most highlypurified HA product available today. In addition, since it is not derivedfrom an avian source (chicken or rooster combs), the risk of reactions relatedto avian proteins is eliminated.(3-8)
EUFLEXXA(TM) received PMA approval from the U.S. Food and DrugAdministration (FDA) on December 3, 2004, and became available to the publicon November 8, 2005. For more information, visit www.EUFLEXXA.com.
(1) IMS National Sales Perspective Data, February 2008
(2) Kirchner M, Marshall D. A double-blind randomized controlled trialcomparing alternate forms of high molecular weight hyaluronan for thetreatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14:154-162.
(3) Schiavinato A, Finesso M, Cortivo R, & Abatangelo G. Comparison of theeffects of intra-articular injections of Hyaluronan and its chemicallycross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin ExpRheumatol. 2002; 20: 445-454.
(4) Goomer RS, Leslie K, Maris T, & Amiel D. Native hyaluronan producesless hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res.2005; 434: 239-245.
(5) Leopold SS, Warme WJ, Pettis PD, & Shott S. Increased frequency ofacute local reaction to intra-articular hylan GF-20 (synvisc) in patientsreceiving more than one course of treatment. J Bone Joint Surg Am. 2002; 84-A:1619-1623.
(6) Puttick MP, Wade JP, Chalmers A, Connell DG, & Rangno KK. Acute localreactions after intraarticular hylan for osteoarthritis of the knee.J Rheumatol. 1995; 22: 1311-1314.
(7) Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, & Schumacher HR. Arethere distinctive inflammatory flares after hylan g-f 20 intraarticularinjections? J Rheumatol. 2002; 29: 2611-2614.
(8) Chen AL, Desai P, Adler EM, & Di Cesare PE. Granulomatous inflammationafter Hylan G-F 20 viscosupplementation of the knee: a report of six cases. JBone Joint Surg Am. 2002;
